Arriva Pharmaceuticals, Inc. has signed an agreement to develop and commercialise the synthetic matrix metalloprotease inhibitor (MMPI) Ilomastat for the treatment of inflammatory respiratory diseases. “This is a further demonstration of our strategy, which aims to build a product pipeline in protease inhibitors and respiratory diseases,” said Martin Preuveneers, Ph.D., Chairman and CEO of Arriva. Read more about Arriva Signs Agreement For Respiratory Disease Treatment[…]